【摘要】 目的观察促红细胞生成素(erythropoietin,EPO)联合参附注射液治疗慢性心力衰竭(chronic heart failure,CHF)的临床疗效。方法将160例CHF患者随机分成对照组(n=40)、EPO组(n=40)、参附注射液组(参附组,n=40)和EPO联合参附注射液组(EPO+参附组,n=40),比较治疗前后各组患者的心功能分级(NYHA)和明尼苏达心力衰竭生活质量评分、左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)、血浆N末端脑钠肽前体(NT-proBNP)水平、再住院率,不良反应发生情况。结果治疗后4组心功能均得到了提高,以EPO+参附组改善最为明显,心功能评级由(3.7±0.47)降至(1.2±0.52),生活质量评分由(46.5±1.41)降为(22.1±2.53),同时NT-proBNP水平均也由治疗前(2712.2±323.30)ng/L降至(352.0±60.52)ng/L,LVEF由(31.3±2.88)%升至(48.1±5.21)%,LVEDD由(67.1±2.35)mm降至(52.1±3.33)mm,再入院率为35.0%,均低于其他三组。结论 EPO联合参附注射液治疗慢性心力衰竭能明显改善心功能、提高生活质量和降低再住院率,显著提高临床疗效。更多还原

【Abstract】 Objective To observe the curative effect of erythropoietin(EPO) combining Shenfu Injection on chronic heart failure(CHF).Methods The patients with CHF(n=160) were randomly divided into control group(routine treatment),EPO group,Shenfu Injection group and EPO combining Shenfu Injection group(combining group,each n=40).The scores of NYHA and Minnesota Heart Failure Quality of Life Scale,LVEF,LVEDD and NT-pro-BNP were recorded in all groups before and after treatment.The rate of re-hospitalization and adverse reactions were observed.Results The heart function was improved in all four groups and was more significant in combining group.To EPO + Shenfu group improved most obviously,the degree of cardiac function decreased from(3.7 ± 0.47) to(1.2 ± 0.52),quality of life scores decreased from the(46.5 ± 1.41) to(22.1 ± 2.53),while NTproBNP levels were also decreased from(2712.2 ± 323.30)ng/L to(352.0 ± 60.52)ng/L,LVEF increased from(31.3 ± 2.88)% to(48.1 ± 5.21)%,LVEDD decreased from(67.1 ± 2.35) mm to(52.1 ± 3.33) mm.,and the readmission was 35.0%,which was lower than other three groups.Conclusion EPO combining Shenfu Injection can significantly improve the heart function,promote the quality of life,reduce the rate of re-hospitalization,and enhance curative effect.更多还原